Monocyte-mediated Augmentation of Human Natural Killer Cell Activity: Conditions, Monocyte and Effector Cell Characteristics
Overview
Authors
Affiliations
The characteristics of the effector cells and monocytes, and conditions required for the monocyte-mediated augmentation of human natural killer (NK) cell activity were investigated. Enriched null cell populations were further fractionated by Percoll centrifugation and used as effector cells. The LGL-enriched fraction was less susceptible than either the unfractionated cells or the other Percoll fractions to the monocyte augmentation when mixed with monocytes in the chromium-release assay and when precultured with monocytes for 12 hr, retrieved by carbonyl iron treatment, and tested for NK activity against K562. This differential susceptibility was reflected at the single cell level. The LGL-enriched Percoll fraction did not display the increase in target-binding cells with lytic activity that was exhibited by the other effector cell preparations after culture with monocytes. No differences in Leu-7 and Leu-11 phenotypes were detected between enriched null cells that had been cultured with and without monocytes for 12 hr. At the monocyte level, it was shown that pretreatment of the monocytes with LPS did not alter their NK-augmenting activity appreciably. Glutaraldehyde-fixed monocytes were not effective, and actinomycin D-treated monocytes were less effective than untreated or irradiated monocytes when mixed with enriched null cells in the assay. Actinomycin D-treated monocytes did not augment and possibly suppressed NK activity tested after 12-hr culture, and irradiated monocytes were less effective for augmenting NK activity than untreated cells. Monocyte-mediated augmentation could be detected when the medium used for null cell-monocyte coculture was supplemented with a) different lots of fetal bovine serum, b) human AB serum, c) autologous serum, or d) no serum. Polymyxin B and indomethacin did not alter the monocyte effect. Finally, the monocyte-mediated augmentation of human NK was not MHC restricted, since allogeneic combinations were also effective. These results suggest that 1) lymphocytes other than LGL participate in the monocyte-mediated augmentation of NK activity, 2) the augmentation is probably activational rather than maturational, 3) the monocytes must be viable to be effective when mixed with null cells during the assay, 4) de novo RNA and/or protein synthesis by the monocytes is required for the monocytes to induce augmented activity in null cells after 12-hr coculture, 5) prostaglandin synthesis and endotoxin are probably not involved in the augmentation, 6) the phenomenon is not MHC restricted, and 7) monocytes may express augmentative and suppressive activities concurrently.
Son B, Roberts R, Ank B, Stiehm E Clin Diagn Lab Immunol. 1996; 3(3):260-4.
PMID: 8705665 PMC: 170325. DOI: 10.1128/cdli.3.3.260-264.1996.
Gaspari A, Fleisher T, Kraemer K J Clin Invest. 1993; 92(3):1135-42.
PMID: 7690772 PMC: 288250. DOI: 10.1172/JCI116682.
Kanar M, Thiele D, Ostensen M, Lipsky P J Clin Immunol. 1988; 8(1):69-79.
PMID: 3259245 DOI: 10.1007/BF00915159.
Furbert-Harris P, Evans C Cancer Immunol Immunother. 1989; 30(2):86-91.
PMID: 2688871 PMC: 11038508. DOI: 10.1007/BF01665958.
Interleukin-2 can induce suppression of human natural killer cell cytotoxicity.
Hellstrand K, HERMODSSON S Clin Exp Immunol. 1989; 77(3):410-6.
PMID: 2509116 PMC: 1542047.